Austin Health

Title
Acute Kidney Injury and Renal Replacement Therapy in Critically Ill COVID-19 Patients: Risk Factors and Outcomes: A Single-Center Experience in Brazil.
Publication Date
2021
Author(s)
Doher, Marisa Petrucelli
Torres de Carvalho, Fabrício Rodrigues
Scherer, Patrícia Faria
Matsui, Thaís Nemoto
Ammirati, Adriano Luiz
Caldin da Silva, Bruno
Barbeiro, Bruna Gomes
Carneiro, Fabiana Dias
Corrêa, Thiago Domingos
Ferraz, Leonardo José Rolim
Dos Santos, Bento Fortunato Cardoso
Pereira, Virgílio Gonçalves
Batista, Marcelo Costa
Monte, Júlio Cesar Martins
Santos, Oscar Fernando Pavão
Bellomo, Rinaldo
Serpa Neto, Ary
Durão, Marcelino de Souza
Subject
Acute kidney injury
COVID-19
Continuous renal replacement therapy
Dialysis
Intensive care unit
Severe acute respiratory syndrome coronavirus 2
Type of document
Journal Article
DOI
10.1159/000513425
Abstract
Critically ill patients with COVID-19 may develop multiple organ dysfunction syndrome, including acute kidney injury (AKI). We report the incidence, risk factors, associations, and outcomes of AKI and renal replacement therapy (RRT) in critically ill COVID-19 patients. We performed a retrospective cohort study of adult patients with COVID-19 diagnosis admitted to the intensive care unit (ICU) between March 2020 and May 2020. Multivariable logistic regression analysis was applied to identify risk factors for the development of AKI and use of RRT. The primary outcome was 60-day mortality after ICU admission. 101 (50.2%) patients developed AKI (72% on the first day of invasive mechanical ventilation [IMV]), and thirty-four (17%) required RRT. Risk factors for AKI included higher baseline Cr (OR 2.50 [1.33-4.69], p = 0.005), diuretic use (OR 4.14 [1.27-13.49], p = 0.019), and IMV (OR 7.60 [1.37-42.05], p = 0.020). A higher C-reactive protein level was an additional risk factor for RRT (OR 2.12 [1.16-4.33], p = 0.023). Overall 60-day mortality was 14.4% {23.8% (n = 24) in the AKI group versus 5% (n = 5) in the non-AKI group (HR 2.79 [1.04-7.49], p = 0.040); and 35.3% (n = 12) in the RRT group versus 10.2% (n = 17) in the non-RRT group, respectively (HR 2.21 [1.01-4.85], p = 0.047)}. AKI was common among critically ill COVID-19 patients and occurred early in association with IMV. One in 6 AKI patients received RRT and 1 in 3 patients treated with RRT died in hospital. These findings provide important prognostic information for clinicians caring for these patients.
Link
Citation
Blood Purification 2021; 50(4-5): 520-530
Jornal Title
Blood Purification

Files:

NameSizeformatDescriptionLink